1
|
Rawson KB, Neuberger T, Smith TB, Bell IJ, Looper RE, Sebahar PR, Haussener TJ, Kanna Reddy HR, Isaacson BM, Shero J, Pasquina PF, Williams DL. Ex vivo comparison of V.A.C.® Granufoam Silver™ and V.A.C.® Granufoam™ loaded with a first-in-class bis-dialkylnorspermidine-terphenyl antibiofilm agent. Biofilm 2023; 6:100142. [PMID: 37484784 PMCID: PMC10359492 DOI: 10.1016/j.bioflm.2023.100142] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/10/2023] [Revised: 07/08/2023] [Accepted: 07/10/2023] [Indexed: 07/25/2023] Open
Abstract
Implementation of negative pressure wound therapy (NPWT) as a standard of care has proven efficacious in reducing both the healing time and likelihood of nosocomial infection among pressure ulcers and traumatic, combat-related injuries. However, current formulations may not target or dramatically reduce bacterial biofilm burden following therapy. The purpose of this study was to determine the antibiofilm efficacy of an open-cell polyurethane (PU) foam (V.A.C.® Granufoam™) loaded with a first-in-class compound (CZ-01179) as the active release agent integrated via lyophilized hydrogel scaffolding. An ex vivo porcine excision wound model was designed to perform antibiofilm efficacy testing in the presence of NPWT. PU foam samples loaded with a 10.0% w/w formulation of CZ-01179 and 0.5% hyaluronic acid were prepared and tested against current standards of care: V.A.C.® Granufoam Silver™ and V.A.C.® Granufoam™. We observed statistically significant reduction of methicillin-resistant Staphylococcus aureus (MRSA) and Acinetobacter baumannii biofilms with the CZ-01179 antibiofilm foam in comparison to current standard of care foams. These findings motivate further development of an antibiofilm PU foam loaded with CZ-01179.
Collapse
Affiliation(s)
- Kaden B. Rawson
- Department of Orthopaedics, University of Utah, Salt Lake City, UT, USA
- Bone and Biofilm Research Lab, University of Utah, Salt Lake City, UT, USA
- Carle Illinois College of Medicine, University of Illinois, Urbana, IL, USA
| | - Travis Neuberger
- Department of Orthopaedics, University of Utah, Salt Lake City, UT, USA
- Bone and Biofilm Research Lab, University of Utah, Salt Lake City, UT, USA
- Department of Biomedical Engineering, University of Utah, UT, USA
- Carle Illinois College of Medicine, University of Illinois, Urbana, IL, USA
| | - Tyler B. Smith
- Department of Orthopaedics, University of Utah, Salt Lake City, UT, USA
- Bone and Biofilm Research Lab, University of Utah, Salt Lake City, UT, USA
| | - Isaac J. Bell
- Department of Orthopaedics, University of Utah, Salt Lake City, UT, USA
- Bone and Biofilm Research Lab, University of Utah, Salt Lake City, UT, USA
| | - Ryan E. Looper
- Department of Chemistry, University of Utah, Salt Lake City, UT, USA
- Curza Global, LLC, Salt Lake City, UT, USA
| | - Paul R. Sebahar
- Department of Chemistry, University of Utah, Salt Lake City, UT, USA
- Curza Global, LLC, Salt Lake City, UT, USA
| | - Travis J. Haussener
- Department of Chemistry, University of Utah, Salt Lake City, UT, USA
- Curza Global, LLC, Salt Lake City, UT, USA
| | | | - Brad M. Isaacson
- Bone and Biofilm Research Lab, University of Utah, Salt Lake City, UT, USA
- The Center for Rehabilitation Sciences Research, Department of Physical Medicine and Rehabilitation, Uniformed Services University, Bethesda, MD, USA
- The Geneva Foundation, Tacoma, WA, USA
| | - John Shero
- Extremity Trauma and Amputation Center of Excellence, Joint Base San Antonio Fort Sam Houston, San Antonio, TX, USA
| | - Paul F. Pasquina
- The Center for Rehabilitation Sciences Research, Department of Physical Medicine and Rehabilitation, Uniformed Services University, Bethesda, MD, USA
- Department of Rehabilitation, Walter Reed National Military Medical Center, Bethesda, MD, USA
| | - Dustin L. Williams
- Department of Orthopaedics, University of Utah, Salt Lake City, UT, USA
- Bone and Biofilm Research Lab, University of Utah, Salt Lake City, UT, USA
- Department of Biomedical Engineering, University of Utah, UT, USA
- Curza Global, LLC, Salt Lake City, UT, USA
- The Center for Rehabilitation Sciences Research, Department of Physical Medicine and Rehabilitation, Uniformed Services University, Bethesda, MD, USA
- Department of Pathology, University of Utah, Salt Lake City, UT, USA
| |
Collapse
|
2
|
Nelli MR, Cantrell RL, Looper RE. Gold Catalyzed 7- endo-dig Hydroaminations Yielding 1,4-Diazepineones. J Org Chem 2023; 88:15975-15982. [PMID: 37890169 DOI: 10.1021/acs.joc.3c01215] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/29/2023]
Abstract
Strategies to access the 1,4-diazepindiones heterocyclic core of the TAN-1057 family of natural products revealed a successful gold-catalyzed hydroamination of yneamide tethered amines. The precursor amino-yneamides are derived from easily accessible 1,2-diamines and alkynoic acids and are efficiently cyclized to the corresponding diazepineones.
Collapse
Affiliation(s)
- Matthew R Nelli
- Department of Chemistry, University of Utah, Salt Lake City, Utah 84112, United States
| | - Rachel L Cantrell
- Department of Chemistry, University of Utah, Salt Lake City, Utah 84112, United States
| | - Ryan E Looper
- Department of Chemistry, University of Utah, Salt Lake City, Utah 84112, United States
| |
Collapse
|
3
|
Shi DD, Savani MR, Levitt MM, Wang AC, Endress JE, Bird CE, Buehler J, Stopka SA, Regan MS, Lin YF, Puliyappadamba VT, Gao W, Khanal J, Evans L, Lee JH, Guo L, Xiao Y, Xu M, Huang B, Jennings RB, Bonal DM, Martin-Sandoval MS, Dang T, Gattie LC, Cameron AB, Lee S, Asara JM, Kornblum HI, Mak TW, Looper RE, Nguyen QD, Signoretti S, Gradl S, Sutter A, Jeffers M, Janzer A, Lehrman MA, Zacharias LG, Mathews TP, Losman JA, Richardson TE, Cahill DP, DeBerardinis RJ, Ligon KL, Xu L, Ly P, Agar NYR, Abdullah KG, Harris IS, Kaelin WG, McBrayer SK. De novo pyrimidine synthesis is a targetable vulnerability in IDH mutant glioma. Cancer Cell 2022; 40:939-956.e16. [PMID: 35985343 PMCID: PMC9515386 DOI: 10.1016/j.ccell.2022.07.011] [Citation(s) in RCA: 35] [Impact Index Per Article: 17.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/30/2021] [Revised: 06/09/2022] [Accepted: 07/26/2022] [Indexed: 12/30/2022]
Abstract
Mutations affecting isocitrate dehydrogenase (IDH) enzymes are prevalent in glioma, leukemia, and other cancers. Although mutant IDH inhibitors are effective against leukemia, they seem to be less active in aggressive glioma, underscoring the need for alternative treatment strategies. Through a chemical synthetic lethality screen, we discovered that IDH1-mutant glioma cells are hypersensitive to drugs targeting enzymes in the de novo pyrimidine nucleotide synthesis pathway, including dihydroorotate dehydrogenase (DHODH). We developed a genetically engineered mouse model of mutant IDH1-driven astrocytoma and used it and multiple patient-derived models to show that the brain-penetrant DHODH inhibitor BAY 2402234 displays monotherapy efficacy against IDH-mutant gliomas. Mechanistically, this reflects an obligate dependence of glioma cells on the de novo pyrimidine synthesis pathway and mutant IDH's ability to sensitize to DNA damage upon nucleotide pool imbalance. Our work outlines a tumor-selective, biomarker-guided therapeutic strategy that is poised for clinical translation.
Collapse
Affiliation(s)
- Diana D Shi
- Department of Radiation Oncology, Dana-Farber/Brigham and Women's Cancer Center, Harvard Medical School, Boston, MA 02215, USA; Children's Medical Center Research Institute, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA
| | - Milan R Savani
- Children's Medical Center Research Institute, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA; Medical Scientist Training Program, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA
| | - Michael M Levitt
- Children's Medical Center Research Institute, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA
| | - Adam C Wang
- Department of Medical Oncology, Dana-Farber Cancer Institute and Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02215, USA
| | - Jennifer E Endress
- Ludwig Cancer Center, Boston, MA 02115, USA; Harvard Medical School, Boston, MA 02115, USA
| | - Cylaina E Bird
- Department of Neurological Surgery, University of Texas Southwestern Medical Center, Dallas, TX 75235, USA
| | - Joseph Buehler
- Children's Medical Center Research Institute, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA
| | - Sylwia A Stopka
- Department of Neurosurgery, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA; Department of Radiology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA
| | - Michael S Regan
- Department of Neurosurgery, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA
| | - Yu-Fen Lin
- Department of Pathology, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA
| | - Vinesh T Puliyappadamba
- Children's Medical Center Research Institute, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA
| | - Wenhua Gao
- Department of Medical Oncology, Dana-Farber Cancer Institute and Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02215, USA
| | - Januka Khanal
- Department of Medical Oncology, Dana-Farber Cancer Institute and Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02215, USA
| | - Laura Evans
- Bayer HealthCare Pharmaceuticals, Inc., Cambridge, MA 02142, USA
| | - Joyce H Lee
- Department of Medical Oncology, Dana-Farber Cancer Institute and Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02215, USA
| | - Lei Guo
- Quantitative Biomedical Research Center, Department of Population & Data Sciences, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA
| | - Yi Xiao
- Children's Medical Center Research Institute, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA
| | - Min Xu
- Children's Medical Center Research Institute, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA
| | - Bofu Huang
- Department of Medical Oncology, Dana-Farber Cancer Institute and Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02215, USA
| | - Rebecca B Jennings
- Department of Medical Oncology, Dana-Farber Cancer Institute and Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02215, USA; Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA
| | - Dennis M Bonal
- Lurie Family Imaging Center, Center for Biomedical Imaging in Oncology, Dana-Farber Cancer Institute, Boston, MA 02210, USA
| | - Misty S Martin-Sandoval
- Children's Medical Center Research Institute, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA
| | - Tammie Dang
- Department of Pharmacology, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA
| | - Lauren C Gattie
- Children's Medical Center Research Institute, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA; Department of Neurological Surgery, University of Texas Southwestern Medical Center, Dallas, TX 75235, USA
| | - Amy B Cameron
- Lurie Family Imaging Center, Center for Biomedical Imaging in Oncology, Dana-Farber Cancer Institute, Boston, MA 02210, USA
| | - Sungwoo Lee
- New Drug Development Center, Daegu-Gyeongbuk Medical Innovation Foundation, Daegu 41061, Republic of Korea
| | - John M Asara
- Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA; Cancer Center, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA
| | - Harley I Kornblum
- Department of Molecular and Medical Pharmacology, University of California Los Angeles, Los Angeles, CA 90095, USA; Department of Psychiatry and Behavioral Sciences, and Semel Institute for Neuroscience and Human Behavior, University of California Los Angeles, Los Angeles, CA 90024, USA
| | - Tak W Mak
- The Campbell Family Institute for Breast Cancer Research, University Health Network, Toronto, ON M5G 2M9, Canada; The Princess Margaret Cancer Centre and Ontario Cancer Institute, University Health Network, Toronto, ON M5G 1L7, Canada; Department of Medical Biophysics, University of Toronto, Toronto, ON M5G 1L7, Canada
| | - Ryan E Looper
- Department of Chemistry, University of Utah, Salt Lake City, UT 84112, USA
| | - Quang-De Nguyen
- Lurie Family Imaging Center, Center for Biomedical Imaging in Oncology, Dana-Farber Cancer Institute, Boston, MA 02210, USA
| | - Sabina Signoretti
- Department of Medical Oncology, Dana-Farber Cancer Institute and Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02215, USA; Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA
| | - Stefan Gradl
- Bayer AG, Muellerstrasse 178, 13353 Berlin, Germany
| | | | - Michael Jeffers
- Bayer HealthCare Pharmaceuticals, Inc., Whippany, NJ 07981, USA
| | | | - Mark A Lehrman
- Department of Pharmacology, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA
| | - Lauren G Zacharias
- Children's Medical Center Research Institute, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA
| | - Thomas P Mathews
- Children's Medical Center Research Institute, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA
| | - Julie-Aurore Losman
- Department of Medical Oncology, Dana-Farber Cancer Institute and Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02215, USA
| | - Timothy E Richardson
- Department of Pathology, Glenn Biggs Institute for Alzheimer's and Neurodegenerative Diseases, University of Texas Health Science Center, San Antonio, TX 78229, USA
| | - Daniel P Cahill
- Department of Neurosurgery, Translational Neuro-Oncology Laboratory, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
| | - Ralph J DeBerardinis
- Children's Medical Center Research Institute, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA; Howard Hughes Medical Institute, Chevy Chase, MD 20815, USA; Department of Pediatrics, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA; Harold C. Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas, TX 75235, USA
| | - Keith L Ligon
- Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA; Department of Oncologic Pathology, Dana-Farber Cancer Institute, Boston, MA 02115, USA; Department of Pathology, Children's Hospital Boston, Boston, MA 02115, USA
| | - Lin Xu
- Quantitative Biomedical Research Center, Department of Population & Data Sciences, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA; Harold C. Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas, TX 75235, USA
| | - Peter Ly
- Department of Pathology, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA
| | - Nathalie Y R Agar
- Department of Neurosurgery, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA; Department of Radiology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA; Department of Cancer Biology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02215, USA
| | - Kalil G Abdullah
- Department of Neurosurgery, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213, USA; Hillman Comprehensive Cancer Center, University of Pittsburgh Medical Center, Pittsburgh, PA 15232, USA
| | - Isaac S Harris
- Wilmot Cancer Institute, University of Rochester Medical Center, Rochester, NY 14642, USA
| | - William G Kaelin
- Department of Medical Oncology, Dana-Farber Cancer Institute and Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02215, USA; Howard Hughes Medical Institute, Chevy Chase, MD 20815, USA.
| | - Samuel K McBrayer
- Children's Medical Center Research Institute, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA; Department of Pediatrics, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA; Harold C. Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas, TX 75235, USA.
| |
Collapse
|
4
|
Rawson KB, Neuberger T, Smith T, Reddy HRK, Haussener TJ, Sebahar PR, Looper RE, Isaacson BM, Shero J, Pasquina PF, Williams DL. Antibiofilm potential of a negative pressure wound therapy foam loaded with a first-in-class tri-alkyl norspermidine-biaryl antibiotic. J Biomed Mater Res B Appl Biomater 2022; 110:1780-1788. [PMID: 35213779 DOI: 10.1002/jbm.b.35035] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/21/2021] [Revised: 01/18/2022] [Accepted: 02/09/2022] [Indexed: 11/07/2022]
Abstract
Negative-pressure wound therapy (NPWT) is commonly utilized to treat traumatic injuries sustained on the modern battlefield. However, NPWT has failed to decrease the incidence of deep tissue infections experienced by Wounded Warriors, despite attempts to integrate common antimicrobials, like Ag+ nanoparticles, into the wound dressing. The purpose of this study was to incorporate a unique antibiofilm compound (CZ-01179) into the polyurethane matrix of NPWT foam via lyophilized hydrogel scaffolding. Foam samples with 2.5%, 5.0%, and 10.0% w/w CZ-01179 were produced and antibiofilm efficacy was compared to the current standards of care: V.A.C.® GRANUFOAM SILVER™ and V.A.C.® GRANUFOAM™. Gravimetric analysis and elution kinetics testing confirmed that this loading technique was both repeatable and controllable. Furthermore, zone of inhibition and antibiofilm efficacy testing showed that foam loaded with CZ-01179 had significantly increased activity against planktonic and biofilm phenotypes of methicillin-resistant Staphylococcus aureus and Acinetobacter baumannii compared to the clinical standards. These findings motivate additional ex vivo and in vivo work with NPWT foam loaded with CZ-01179 with the overall objective of reducing NPWT-associated infections that complicate battlefield-related and other wounds.
Collapse
Affiliation(s)
- Kaden B Rawson
- Department of Orthopaedics, University of Utah, Salt Lake City, Utah, USA
| | - Travis Neuberger
- Department of Orthopaedics, University of Utah, Salt Lake City, Utah, USA
| | - Tyler Smith
- Department of Orthopaedics, University of Utah, Salt Lake City, Utah, USA
| | | | | | - Paul R Sebahar
- Curza Global, Salt Lake City, Utah, USA.,Department of Chemistry, University of Utah, Salt Lake City, Utah, USA
| | - Ryan E Looper
- Curza Global, Salt Lake City, Utah, USA.,Department of Chemistry, University of Utah, Salt Lake City, Utah, USA
| | - Brad M Isaacson
- The Geneva Foundation, Tacoma, Washington, USA.,Department of Physical Medicine and Rehabilitation, Center for Rehabilitation Sciences Research, Uniformed Services University of the Health Sciences, Bethesda, Maryland, USA
| | - John Shero
- Department of Physical Medicine and Rehabilitation, Center for Rehabilitation Sciences Research, Uniformed Services University of the Health Sciences, Bethesda, Maryland, USA.,Extremity Trauma and Amputation Center of Excellence, San Antonio, Texas, USA
| | - Paul F Pasquina
- Department of Physical Medicine and Rehabilitation, Center for Rehabilitation Sciences Research, Uniformed Services University of the Health Sciences, Bethesda, Maryland, USA.,Department of Rehabilitation, Walter Reed National Military Medical Center, Bethesda, Maryland, USA
| | - Dustin L Williams
- Department of Orthopaedics, University of Utah, Salt Lake City, Utah, USA.,Curza Global, Salt Lake City, Utah, USA.,Department of Physical Medicine and Rehabilitation, Center for Rehabilitation Sciences Research, Uniformed Services University of the Health Sciences, Bethesda, Maryland, USA.,Department of Bioengineering, University of Utah, Salt Lake City, Utah, USA.,Department of Pathology, University of Utah, Salt Lake City, Utah, USA
| |
Collapse
|
5
|
Abstract
Without question, natural products have provided the lion share of leads, if not drugs themselves, for the treatment of bacterial infections. The bacterial arms race, fueled by selection and survival pressures has delivered a natural arsenal of small molecules targeting the most essential of life processes. Antibiotics that target these critical intracellular processes face the formidable defense of both penetrating a bacterial cell membrane and avoiding efflux to exert their effect. These challenges are especially effective in Gram-negative (Gram-(-)) bacteria, which have a double membrane structure and efficient efflux systems from the combination of outer-membrane porins and inner membrane proton pumps. In this landscape of offense and defense, our clinically used antibiotics have only successfully targeted three intracellular processes for therapeutic intervention in Gram-(-) bacteria: dihydrofolate biosynthesis, transcription, and translation. Not surprisingly, such critical survival machinery is a popular target for bacterial warfare, and eight of our 14 classes of commonly used antibiotics target translation with the bacterial ribosome remaining one the most vetted targets for antimicrobial therapy. On the plus side, its anionic character attracts cationic inhibitors, which are generally more capable of penetrating the bacterial cell wall, and clinical resistance rates are usually manageable as mutation of such a highly evolved machine is difficult. On the down side, this highly evolved machine renders it difficult to inhibit selectively, and the inhibition of prokaryotic translation versus both eukaryotic cellular and mitochondrial translation is critical for clinical development and minimization of undesired toxicities.A class of natural products known as the "nucleoside antibiotics" have historically been recognized as universal inhibitors of the ribosome and can inhibit translation in prokaryotes, eukaryotes, and archaea. While they have served an essential role in dissecting the biochemical underpinnings of the enzymatic functions of the ribosome, they have not proven therapeutically useful as they target the highly conserved rRNA in the P-site and are toxic to mammalian cells. In this Account, we describe our studies on the natural product amicetin, a nucleoside antibiotic that we have demonstrated to break the rule of being a universal translation inhibitor. While the cytosine of amicetin mimics C75 of the 3'-CCA tail of the P-site tRNA akin to other nucleoside antibiotics, we advance a hypothesis that amicetin's unique interaction with the ribosomal protein uL16 exploits an untapped mechanism for selectively targeting the bacterial ribosome. A complex molecule comprised of a nucleoside, carbohydrates and amino acids, amicetin is also chemically unstable. Our initial attempts to stabilize and simplify this scaffold are presented with the ultimate goal of rebuilding the compound with improved penetrance to bacterial cells. If successful, this scaffold would demonstrate a path forward for a new class of antibiotics capable of selectively targeting the ribosomal P-site.
Collapse
Affiliation(s)
- Matthew R. Nelli
- Department of Chemistry, University of Utah, Salt Lake City Utah 84103, United States
| | - Kendall N. Heitmeier
- Department of Chemistry, University of Utah, Salt Lake City Utah 84103, United States
| | - Ryan E. Looper
- Department of Chemistry, University of Utah, Salt Lake City Utah 84103, United States
| |
Collapse
|
6
|
|
7
|
Miller M, Rogers JC, Badham MA, Cadenas L, Brightwell E, Adams J, Tyler C, Sebahar PR, Haussener TJ, Reddy HRK, Looper RE, Williams DL. Examination of a first-in-class bis-dialkylnorspermidine-terphenyl antibiotic in topical formulation against mono and polymicrobial biofilms. PLoS One 2020; 15:e0234832. [PMID: 33075071 PMCID: PMC7571676 DOI: 10.1371/journal.pone.0234832] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/28/2020] [Accepted: 09/17/2020] [Indexed: 12/11/2022] Open
Abstract
Biofilm-impaired tissue is a significant factor in chronic wounds such as diabetic foot ulcers. Most, if not all, anti-biotics in clinical use have been optimized against planktonic phenotypes. In this study, an in vitro assessment was performed to determine the potential efficacy of a first-in-class series of antibiofilm antibiotics and compare outcomes to current clinical standards of care. The agent, CZ-01179, was formulated into a hydrogel and tested against mature biofilms of a clinical isolate of methicillin-resistant Staphylococcus aureus and Pseudomonas aeruginosa ATCC 27853 using two separate methods. In the first method, biofilms were grown on cellulose discs on an agar surface. Topical agents were spread on gauze and placed over the biofilms for 24 h. Biofilms were quantified and imaged with confocal and scanning electron microscopy. In the second method, biofilms were grown on bioabsorbable collagen coupons in a modified CDC biofilm reactor. Coupons were immersed in treatment for 24 h. The first method was limited in its ability to assess efficacy. Efficacy profiles against biofilms grown on collagen were more definitive, with CZ-01179 gel eradicating well-established biofilms to a greater degree compared to clinical standards. In conclusion, CZ-01179 may be a promising topical agent that targets the biofilm phenotype. Pre-clinical work is currently being performed to determine the translatable potential of CZ-01179 gel.
Collapse
Affiliation(s)
- Mariël Miller
- George E. Wahlen Department of Veterans Affairs Medical Center, Salt Lake City, UT, United States of America
- Department of Orthopaedics, University of Utah, Salt Lake City, UT, United States of America
| | - Jeffery C. Rogers
- George E. Wahlen Department of Veterans Affairs Medical Center, Salt Lake City, UT, United States of America
- Department of Orthopaedics, University of Utah, Salt Lake City, UT, United States of America
| | - Marissa A. Badham
- George E. Wahlen Department of Veterans Affairs Medical Center, Salt Lake City, UT, United States of America
- Department of Orthopaedics, University of Utah, Salt Lake City, UT, United States of America
| | - Lousili Cadenas
- George E. Wahlen Department of Veterans Affairs Medical Center, Salt Lake City, UT, United States of America
- Department of Orthopaedics, University of Utah, Salt Lake City, UT, United States of America
| | - Eian Brightwell
- George E. Wahlen Department of Veterans Affairs Medical Center, Salt Lake City, UT, United States of America
- Department of Orthopaedics, University of Utah, Salt Lake City, UT, United States of America
| | - Jacob Adams
- George E. Wahlen Department of Veterans Affairs Medical Center, Salt Lake City, UT, United States of America
- Department of Orthopaedics, University of Utah, Salt Lake City, UT, United States of America
| | - Cole Tyler
- George E. Wahlen Department of Veterans Affairs Medical Center, Salt Lake City, UT, United States of America
- Department of Orthopaedics, University of Utah, Salt Lake City, UT, United States of America
| | - Paul R. Sebahar
- Curza Global, LLC Provo, UT, United States of America
- Department of Chemistry, University of Utah, Salt Lake City, UT, United States of America
| | - Travis J. Haussener
- Curza Global, LLC Provo, UT, United States of America
- Department of Chemistry, University of Utah, Salt Lake City, UT, United States of America
| | - Hariprasada Reddy Kanna Reddy
- Curza Global, LLC Provo, UT, United States of America
- Department of Chemistry, University of Utah, Salt Lake City, UT, United States of America
| | - Ryan E. Looper
- Curza Global, LLC Provo, UT, United States of America
- Department of Chemistry, University of Utah, Salt Lake City, UT, United States of America
| | - Dustin L. Williams
- George E. Wahlen Department of Veterans Affairs Medical Center, Salt Lake City, UT, United States of America
- Department of Orthopaedics, University of Utah, Salt Lake City, UT, United States of America
- Curza Global, LLC Provo, UT, United States of America
- Department of Pathology, University of Utah, Salt Lake City, UT, United States of America
- Department of Bioengineering, University of Utah, Salt Lake City, UT, United States of America
- Department of Physical Medicine and Rehabilitation, Uniformed Services University, Bethesda, MD, United States of America
- * E-mail:
| |
Collapse
|
8
|
Serrano CM, Kannareddy HR, Eiler D, Koch M, Tresco BIC, Barrows LR, Vanderlinden RT, Testa CA, Sebahar PR, Looper RE. Unifying the Aminohexopyranose- and Peptidyl-Nucleoside Antibiotics: Implications for Antibiotic Design. Angew Chem Int Ed Engl 2020; 59:11330-11333. [PMID: 32342623 PMCID: PMC8186834 DOI: 10.1002/anie.202003094] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/28/2020] [Revised: 04/17/2020] [Indexed: 11/09/2022]
Abstract
In search of new anti-tuberculars compatible with anti-retroviral therapy we re-identified amicetin as a lead compound. Amicetin's binding to the 70S ribosomal subunit of Thermus thermophilus (Tth) has been unambiguously determined by crystallography and reveals it to occupy the peptidyl transferase center P-site of the ribosome. The amicetin binding site overlaps significantly with that of the well-known protein synthesis inhibitor balsticidin S. Amicetin, however, is the first compound structurally characterized to bind to the P-site with demonstrated selectivity for the inhibition of prokaryotic translation. The natural product-ribosome structure enabled the synthesis of simplified analogues that retained both potency and selectivity for the inhibition of prokaryotic translation.
Collapse
Affiliation(s)
- Catherine M. Serrano
- Department of Chemistry, University of Utah, 315 S 1400 E, Salt Lake City, UT 84112 (USA)
| | | | - Daniel Eiler
- Department of Molecular Biophysics and Biochemistry, Yale University, 266 Whitney Ave., New Haven, CT 06250 (USA)
| | - Michael Koch
- Department of Pharmacology and Toxicology, University of Utah, 30 South 1900 East, Salt Lake City, Utah, 84112 (USA)
| | - Ben I. C. Tresco
- Department of Chemistry, University of Utah, 315 S 1400 E, Salt Lake City, UT 84112 (USA)
| | - Louis R. Barrows
- Department of Pharmacology and Toxicology, University of Utah, 30 South 1900 East, Salt Lake City, Utah, 84112 (USA)
| | - Ryan T. Vanderlinden
- Synthetic and Medicinal Chemistry Core Facility, University of Utah, 315 S 1400 E, Salt Lake City, UT 84112 (USA)
| | - Charles A. Testa
- Synthetic and Medicinal Chemistry Core Facility, University of Utah, 315 S 1400 E, Salt Lake City, UT 84112 (USA)
| | - Paul R. Sebahar
- Synthetic and Medicinal Chemistry Core Facility, University of Utah, 315 S 1400 E, Salt Lake City, UT 84112 (USA)
| | - Ryan E. Looper
- Department of Chemistry, University of Utah, 315 S 1400 E, Salt Lake City, UT 84112 (USA)
- Synthetic and Medicinal Chemistry Core Facility, University of Utah, 315 S 1400 E, Salt Lake City, UT 84112 (USA)
| |
Collapse
|
9
|
Serrano CM, Kanna Reddy HR, Eiler D, Koch M, Tresco BIC, Barrows LR, VanderLinden RT, Testa CA, Sebahar PR, Looper RE. Unifying the Aminohexopyranose‐ and Peptidyl‐Nucleoside Antibiotics: Implications for Antibiotic Design. Angew Chem Int Ed Engl 2020. [DOI: 10.1002/ange.202003094] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Affiliation(s)
- Catherine M. Serrano
- Department of Chemistry University of Utah 315 S 1400 E Salt Lake City UT 84112 USA
| | | | - Daniel Eiler
- Department of Molecular Biophysics and Biochemistry Yale University 266 Whitney Ave. New Haven CT 06250 USA
| | - Michael Koch
- Department of Pharmacology and Toxicology University of Utah 30 South 1900 East Salt Lake City UT 84112 USA
| | - Ben I. C. Tresco
- Department of Chemistry University of Utah 315 S 1400 E Salt Lake City UT 84112 USA
| | - Louis R. Barrows
- Department of Pharmacology and Toxicology University of Utah 30 South 1900 East Salt Lake City UT 84112 USA
| | - Ryan T. VanderLinden
- Synthetic and Medicinal Chemistry Core Facility University of Utah 315 S 1400 E Salt Lake City UT 84112 USA
| | - Charles A. Testa
- Synthetic and Medicinal Chemistry Core Facility University of Utah 315 S 1400 E Salt Lake City UT 84112 USA
| | - Paul R. Sebahar
- Synthetic and Medicinal Chemistry Core Facility University of Utah 315 S 1400 E Salt Lake City UT 84112 USA
| | - Ryan E. Looper
- Department of Chemistry University of Utah 315 S 1400 E Salt Lake City UT 84112 USA
- Synthetic and Medicinal Chemistry Core Facility University of Utah 315 S 1400 E Salt Lake City UT 84112 USA
| |
Collapse
|
10
|
Philip B, Yu DX, Silvis MR, Shin CH, Robinson JP, Robinson GL, Welker AE, Angel SN, Tripp SR, Sonnen JA, VanBrocklin MW, Gibbons RJ, Looper RE, Colman H, Holmen SL. Mutant IDH1 Promotes Glioma Formation In Vivo. Cell Rep 2019; 23:1553-1564. [PMID: 29719265 PMCID: PMC6032974 DOI: 10.1016/j.celrep.2018.03.133] [Citation(s) in RCA: 53] [Impact Index Per Article: 10.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/03/2018] [Revised: 02/23/2018] [Accepted: 03/29/2018] [Indexed: 02/08/2023] Open
Abstract
Isocitrate dehydrogenase 1 (IDH1) is the most commonly mutated gene in grade II–III glioma and secondary glioblastoma (GBM). A causal role for IDH1R132H in gliomagenesis has been proposed, but functional validation in vivo has not been demonstrated. In this study, we assessed the role of IDH1R132H in glioma development in the context of clinically relevant cooperating genetic alterations in vitro and in vivo. Immortal astrocytes expressing IDH1R132H exhibited elevated (R)-2-hydroxyglutarate levels, reduced NADPH, increased proliferation, and anchorage-independent growth. Although not sufficient on its own, IDH1R132H cooperated with PDGFA and loss of Cdkn2a, Atrx, and Pten to promote glioma development in vivo. These tumors resembled pro-neural human mutant IDH1 GBM genetically, histologically, and functionally. Our findings support the hypothesis that IDH1R132H promotes glioma development. This model enhances our understanding of the biology of IDH1R132H-driven gliomas and facilitates testing of therapeutic strategies designed to combat this deadly disease.
Collapse
Affiliation(s)
- Beatrice Philip
- Huntsman Cancer Institute, University of Utah Health Sciences Center, Salt Lake City, UT 84112, USA; Department of Surgery, University of Utah Health Sciences Center, Salt Lake City, UT 84112, USA
| | - Diana X Yu
- Huntsman Cancer Institute, University of Utah Health Sciences Center, Salt Lake City, UT 84112, USA; Department of Surgery, University of Utah Health Sciences Center, Salt Lake City, UT 84112, USA
| | - Mark R Silvis
- Huntsman Cancer Institute, University of Utah Health Sciences Center, Salt Lake City, UT 84112, USA; Department of Surgery, University of Utah Health Sciences Center, Salt Lake City, UT 84112, USA
| | - Clifford H Shin
- Huntsman Cancer Institute, University of Utah Health Sciences Center, Salt Lake City, UT 84112, USA; Department of Oncological Sciences, University of Utah Health Sciences Center, Salt Lake City, UT 84112, USA
| | - James P Robinson
- Hormel Institute, University of Minnesota, 801 16(th) Avenue NE, Austin, MN 55912, USA
| | - Gemma L Robinson
- Huntsman Cancer Institute, University of Utah Health Sciences Center, Salt Lake City, UT 84112, USA; Department of Surgery, University of Utah Health Sciences Center, Salt Lake City, UT 84112, USA
| | - Adam E Welker
- Huntsman Cancer Institute, University of Utah Health Sciences Center, Salt Lake City, UT 84112, USA
| | - Stephanie N Angel
- Huntsman Cancer Institute, University of Utah Health Sciences Center, Salt Lake City, UT 84112, USA; Department of Surgery, University of Utah Health Sciences Center, Salt Lake City, UT 84112, USA
| | - Sheryl R Tripp
- ARUP Institute for Clinical and Experimental Pathology, Salt Lake City, UT 84108, USA
| | - Joshua A Sonnen
- ARUP Institute for Clinical and Experimental Pathology, Salt Lake City, UT 84108, USA; Department of Pathology, University of Utah Health Sciences Center, Salt Lake City, UT 84112, USA
| | - Matthew W VanBrocklin
- Huntsman Cancer Institute, University of Utah Health Sciences Center, Salt Lake City, UT 84112, USA; Department of Surgery, University of Utah Health Sciences Center, Salt Lake City, UT 84112, USA; Department of Oncological Sciences, University of Utah Health Sciences Center, Salt Lake City, UT 84112, USA
| | - Richard J Gibbons
- MRC Molecular Haematology Unit, Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, UK
| | - Ryan E Looper
- Department of Chemistry, University of Utah, Salt Lake City, UT 84112, USA
| | - Howard Colman
- Huntsman Cancer Institute, University of Utah Health Sciences Center, Salt Lake City, UT 84112, USA; Department of Neurosurgery, University of Utah Health Sciences Center, Salt Lake City, UT 84112, USA
| | - Sheri L Holmen
- Huntsman Cancer Institute, University of Utah Health Sciences Center, Salt Lake City, UT 84112, USA; Department of Surgery, University of Utah Health Sciences Center, Salt Lake City, UT 84112, USA; Department of Oncological Sciences, University of Utah Health Sciences Center, Salt Lake City, UT 84112, USA.
| |
Collapse
|
11
|
Affiliation(s)
- Srinivas R. Paladugu
- Department of Chemistry, University of Utah, 315 S 1400 E, Salt Lake City, Utah 84112, United States
| | - Chintelle K. James
- Department of Chemistry, University of Utah, 315 S 1400 E, Salt Lake City, Utah 84112, United States
| | - Ryan E. Looper
- Department of Chemistry, University of Utah, 315 S 1400 E, Salt Lake City, Utah 84112, United States
| |
Collapse
|
12
|
Ashton NN, Allyn G, Porter ST, Haussener TJ, Sebahar PR, Looper RE, Williams DL. In vitro testing of a first-in-class tri-alkylnorspermidine-biaryl antibiotic in an anti-biofilm silicone coating. Acta Biomater 2019; 93:25-35. [PMID: 30769135 DOI: 10.1016/j.actbio.2019.02.010] [Citation(s) in RCA: 16] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/18/2018] [Revised: 01/22/2019] [Accepted: 02/09/2019] [Indexed: 01/02/2023]
Abstract
Biofilm-related infection is among the worst complication to prosthetic joint replacement procedures; once established on the implant surface, biofilms show strong recalcitrance to clinical antibiotic therapy, frequently requiring costly revision procedures and prolonged systemic antibiotics for their removal. A well-designed active release coating might assist host immunity in clearing bacterial contaminants within the narrow perioperative window and ultimately prevent microbial colonization of the joint prosthesis. A first-in-class compound (CZ-01127) was tested as the active release agent in a silicone (Si) coating using an in vitro dynamic flow model of surgical site contamination and compared with analogous coatings containing clinical gold-standard antibiotics vancomycin and gentamicin; the CZ-01127 coating outperformed both vancomycin and gentamicin coatings and was the only to decrease the methicillin-resistant Staphylococcus aureus (MRSA) inocula below detectable limits for the first 3 days. The antimicrobial activity of CZ-01127, and for comparison vancomycin and gentamicin, were characterized against both planktonic and biofilm MRSA using the minimum inhibitory concentration (MIC) assay, serial passages, and serial dilution tests against established biofilms grown with a CBR 90 CDC biofilm reactor. Despite a similar MIC (1 µg/ml) and behavior in a 25-day serial passage analysis, CZ-01127 displayed much greater bactericidal activity against established biofilms and was the only to decrease biofilm colony forming units (CFUs) below detectable limits at the highest concentration tested (500 µg/ml). Coating release profiles were characterized using ATR-FTIR and displayed burst release kinetics within the decisive period of the perioperative window suggesting the silicon carrier is broadly useful for screening antibiotic compound for local delivery applications. STATEMENT OF SIGNIFICANCE: With an aging population, an increasing number of people are undergoing total joint replacement procedures in which diseased joint tissues are replaced with permanent metallic implants. Some of these procedures are burdened by costly and debilitating infections. A promising approach to prevent infections is the use of an antimicrobial coating on the surface of the implant which releases antibiotics into the surgical site to prevent infection. In this study, we tested a new antibiotic compound formulated in a silicone coating. Data showed that this compound was more effective at killing pathogenic methicillin resistant Staphylococcus aureus (MRSA) bacteria than two clinical gold-standard antibiotics-vancomycin and gentamicin-and could be a promising agent for antimicrobial coating technologies.
Collapse
Affiliation(s)
- Nicholas N Ashton
- George E. Wahlen Department of Veterans Affairs, Salt Lake City, UT, United States; Department of Orthopaedics, University of Utah, Salt Lake City, UT, United States
| | - Gina Allyn
- George E. Wahlen Department of Veterans Affairs, Salt Lake City, UT, United States; Department of Orthopaedics, University of Utah, Salt Lake City, UT, United States
| | - Scott T Porter
- George E. Wahlen Department of Veterans Affairs, Salt Lake City, UT, United States; Department of Orthopaedics, University of Utah, Salt Lake City, UT, United States
| | - Travis J Haussener
- Curza Global, LLC, Salt Lake City, UT, United States; Synthetic and Medicinal Chemistry Core, University of Utah, Salt Lake City, UT, United States
| | - Paul R Sebahar
- Curza Global, LLC, Salt Lake City, UT, United States; Synthetic and Medicinal Chemistry Core, University of Utah, Salt Lake City, UT, United States
| | - Ryan E Looper
- Curza Global, LLC, Salt Lake City, UT, United States; Synthetic and Medicinal Chemistry Core, University of Utah, Salt Lake City, UT, United States; Department of Chemistry, University of Utah, Salt Lake City, UT, United States
| | - Dustin L Williams
- George E. Wahlen Department of Veterans Affairs, Salt Lake City, UT, United States; Department of Orthopaedics, University of Utah, Salt Lake City, UT, United States; Curza Global, LLC, Salt Lake City, UT, United States; Department of Pathology, University of Utah, Salt Lake City, UT, United States; Department of Bioengineering, University of Utah, Salt Lake City, UT, United States; Department of Physical Medicine and Rehabilitation, Uniformed Services University of the Health Sciences, Bethesda, MD, United States.
| |
Collapse
|
13
|
Williams DL, Epperson RT, Ashton NN, Taylor NB, Kawaguchi B, Olsen RE, Haussener TJ, Sebahar PR, Allyn G, Looper RE. In vivo analysis of a first-in-class tri-alkyl norspermidine-biaryl antibiotic in an active release coating to reduce the risk of implant-related infection. Acta Biomater 2019; 93:36-49. [PMID: 30710710 DOI: 10.1016/j.actbio.2019.01.055] [Citation(s) in RCA: 17] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/16/2018] [Revised: 01/24/2019] [Accepted: 01/28/2019] [Indexed: 12/31/2022]
Abstract
Prosthetic joint infection (PJI) is a well-known and persisting problem. Active release coatings have promise to provide early protection to an implant by eradicating small colony biofilm contaminants or planktonic bacteria that can form biofilm. Traditional antibiotics can be limited as active release agents in that they have limited effect against biofilms and develop resistance at sub-lethal concentrations. A unique first-in-class compound (CZ-01127) was assessed as the active release agent in a silicone (Si)-based coating to prevent PJI in a sheep model of joint space infection. Titanium (Ti) plugs contained a porous coated Ti (PCTi) region and polymer-coated region. Plugs were implanted into a femoral condyle of sheep to assess the effect of the Si polymer on cancellous bone ingrowth, the effect of CZ-01127 on bone ingrowth, and the ability of CZ-01127 to prevent PJI. Microbiological results showed that CZ-01127 was able to eradicate bacteria in the local region of the implanted plugs. Data further showed that Si did not adversely affect bone ingrowth. However, bacteria that reached the joint space (synovium) were not fully eradicated. Outcomes suggested that the CZ-01127 coating provided local protection to the implant system in a challenging model, the design of which could be beneficial for testing future antimicrobial therapies for PJI. STATEMENT OF SIGNIFICANCE: Periprosthetic joint infection (PJI) is now commonplace, and constitutes an underlying problem that patients and physicians face. Active release antibiotic coatings have potential to prevent these infections. Traditional antibiotics are limited in their ability to eradicate bacteria that reside in biofilms, and are more susceptible to resistance development. This study addressed these limitations by testing the efficacy of a unique antimicrobial compound in a coating that was tested in a challenging sheep model of PJI. The unique coating was able to eradicate bacteria and prevent infection in the environment adjacent to the implant. Bacteria that escaped into the joint space still caused infection, yet benchmark data can be used to optimize the coating and translate it toward clinical use.
Collapse
Affiliation(s)
- Dustin L Williams
- George E. Wahlen Department of Veterans Affairs, Salt Lake City, UT, United States; Department of Orthopaedics, University of Utah, Salt Lake City, UT, United States; Department of Pathology, University of Utah, Salt Lake City, UT, United States; Department of Bioengineering, University of Utah, Salt Lake City, UT, United States; Department of Physical Medicine and Rehabilitation, Uniformed Services University of the Health Sciences, Bethesda, MD, United States; Curza Global, LLC, Salt Lake City, UT, United States.
| | - Richard T Epperson
- George E. Wahlen Department of Veterans Affairs, Salt Lake City, UT, United States; Department of Orthopaedics, University of Utah, Salt Lake City, UT, United States
| | - Nicholas N Ashton
- George E. Wahlen Department of Veterans Affairs, Salt Lake City, UT, United States; Department of Orthopaedics, University of Utah, Salt Lake City, UT, United States
| | - Nicholas B Taylor
- George E. Wahlen Department of Veterans Affairs, Salt Lake City, UT, United States; Department of Orthopaedics, University of Utah, Salt Lake City, UT, United States
| | - Brooke Kawaguchi
- George E. Wahlen Department of Veterans Affairs, Salt Lake City, UT, United States; Department of Orthopaedics, University of Utah, Salt Lake City, UT, United States
| | - Raymond E Olsen
- George E. Wahlen Department of Veterans Affairs, Salt Lake City, UT, United States; Department of Orthopaedics, University of Utah, Salt Lake City, UT, United States
| | - Travis J Haussener
- Curza Global, LLC, Salt Lake City, UT, United States; Synthetic and Medicinal Chemistry Core, University of Utah, Salt Lake City, UT, United States
| | - Paul R Sebahar
- Curza Global, LLC, Salt Lake City, UT, United States; Synthetic and Medicinal Chemistry Core, University of Utah, Salt Lake City, UT, United States
| | - Gina Allyn
- George E. Wahlen Department of Veterans Affairs, Salt Lake City, UT, United States; Department of Orthopaedics, University of Utah, Salt Lake City, UT, United States
| | - Ryan E Looper
- Curza Global, LLC, Salt Lake City, UT, United States; Synthetic and Medicinal Chemistry Core, University of Utah, Salt Lake City, UT, United States; Department of Chemistry, University of Utah, Salt Lake City, UT, United States
| |
Collapse
|
14
|
Williams DL, Smith SR, Peterson BR, Allyn G, Cadenas L, Epperson RT, Looper RE. Growth substrate may influence biofilm susceptibility to antibiotics. PLoS One 2019; 14:e0206774. [PMID: 30870411 PMCID: PMC6417642 DOI: 10.1371/journal.pone.0206774] [Citation(s) in RCA: 17] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/16/2018] [Accepted: 02/21/2019] [Indexed: 12/04/2022] Open
Abstract
The CDC biofilm reactor is a robust culture system with high reproducibility in which biofilms can be grown for a wide variety of analyses. Multiple material types are available as growth substrates, yet data from biofilms grown on biologically relevant materials is scarce, particularly for antibiotic efficacy against differentially supported biofilms. In this study, CDC reactor holders were modified to allow growth of biofilms on collagen, a biologically relevant substrate. Susceptibility to multiple antibiotics was compared between biofilms of varying species grown on collagen versus standard polycarbonate coupons. Data indicated that in 13/18 instances, biofilms on polycarbonate were more susceptible to antibiotics than those on collagen, suggesting that when grown on a complex substrate, biofilms may be more tolerant to antibiotics. These outcomes may influence the translatability of antibiotic susceptibility profiles that have been collected for biofilms on hard plastic materials. Data may also help to advance information on antibiotic susceptibility testing of biofilms grown on biologically relevant materials for future in vitro and in vivo applications.
Collapse
Affiliation(s)
- Dustin L. Williams
- George E. Wahlen Department of Veterans Affairs, Salt Lake City, UT, United States of America
- Department of Orthopaedics, University of Utah, Salt Lake City, UT, United States of America
- Department of Pathology, University of Utah, Salt Lake City, UT, United States of America
- Department of Bioengineering, University of Utah, Salt Lake City, UT, United States of America
- Department of Physical Medicine and Rehabilitation, Uniformed Services University, Bethesda, MD, United States of America
- * E-mail:
| | - Scott R. Smith
- George E. Wahlen Department of Veterans Affairs, Salt Lake City, UT, United States of America
- Department of Orthopaedics, University of Utah, Salt Lake City, UT, United States of America
| | - Brittany R. Peterson
- George E. Wahlen Department of Veterans Affairs, Salt Lake City, UT, United States of America
- Department of Orthopaedics, University of Utah, Salt Lake City, UT, United States of America
| | - Gina Allyn
- George E. Wahlen Department of Veterans Affairs, Salt Lake City, UT, United States of America
- Department of Orthopaedics, University of Utah, Salt Lake City, UT, United States of America
| | - Lousili Cadenas
- George E. Wahlen Department of Veterans Affairs, Salt Lake City, UT, United States of America
- Department of Orthopaedics, University of Utah, Salt Lake City, UT, United States of America
| | - Richard Tyler Epperson
- George E. Wahlen Department of Veterans Affairs, Salt Lake City, UT, United States of America
- Department of Orthopaedics, University of Utah, Salt Lake City, UT, United States of America
| | - Ryan E. Looper
- Department of Chemistry, University of Utah, Salt Lake City, UT, United States of America
| |
Collapse
|
15
|
Vaden RM, Guillen KP, Salvant JM, Santiago CB, Gibbons JB, Pathi SS, Arunachalam S, Sigman MS, Looper RE, Welm BE. A Cancer-Selective Zinc Ionophore Inspired by the Natural Product Naamidine A. ACS Chem Biol 2019; 14:106-117. [PMID: 30571086 DOI: 10.1021/acschembio.8b00977] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Abstract
We present data demonstrating the natural product mimic, zinaamidole A (ZNA), is a modulator of metal ion homeostasis causing cancer-selective cell death by specifically inducing cellular Zn2+-uptake in transformed cells. ZNA's cancer selectivity was evaluated using metastatic, patient-derived breast cancer cells, established human breast cancer cell lines, and three-dimensional organoid models derived from normal and transformed mouse mammary glands. Structural analysis of ZNA demonstrated that the compound interacts with zinc through the N2-acyl-2-aminoimidazole core. Combination treatment with ZnSO4 strongly potentiated ZNA's cancer-specific cell death mechanism, an effect that was not observed with other transition metals. We show that Zn2+-dyshomeostasis induced by ZNA is unique and markedly more selective than other known Zn2+-interacting compounds such as clioquinol. The in vivo bioactivity of ZNA was also assessed and revealed that tumor-bearing mice treated with ZNA had improved survival outcomes. Collectively, these data demonstrate that the N2-acyl-2-aminoimidazole core of ZNA represents a powerful chemotype to induce cell death in cancer cells concurrently with a disruption in zinc homeostasis.
Collapse
Affiliation(s)
- Rachel M. Vaden
- Department of Chemistry, University of Utah, 315 S 1400 E, Salt Lake City, Utah 84112, United States
| | | | - Justin M. Salvant
- Department of Chemistry, University of Utah, 315 S 1400 E, Salt Lake City, Utah 84112, United States
| | - Celine B. Santiago
- Department of Chemistry, University of Utah, 315 S 1400 E, Salt Lake City, Utah 84112, United States
| | - Joseph B. Gibbons
- Department of Chemistry, University of Utah, 315 S 1400 E, Salt Lake City, Utah 84112, United States
| | | | | | - Matthew S. Sigman
- Department of Chemistry, University of Utah, 315 S 1400 E, Salt Lake City, Utah 84112, United States
| | - Ryan E. Looper
- Department of Chemistry, University of Utah, 315 S 1400 E, Salt Lake City, Utah 84112, United States
| | | |
Collapse
|
16
|
McBrayer SK, Mayers JR, DiNatale GJ, Shi DD, Khanal J, Chakraborty AA, Sarosiek KA, Briggs KJ, Robbins AK, Sewastianik T, Shareef SJ, Olenchock BA, Parker SJ, Tateishi K, Spinelli JB, Islam M, Haigis MC, Looper RE, Ligon KL, Bernstein BE, Carrasco RD, Cahill DP, Asara JM, Metallo CM, Yennawar NH, Vander Heiden MG, Kaelin WG. Transaminase Inhibition by 2-Hydroxyglutarate Impairs Glutamate Biosynthesis and Redox Homeostasis in Glioma. Cell 2018; 175:101-116.e25. [PMID: 30220459 DOI: 10.1016/j.cell.2018.08.038] [Citation(s) in RCA: 202] [Impact Index Per Article: 33.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/25/2017] [Revised: 06/22/2018] [Accepted: 08/17/2018] [Indexed: 12/31/2022]
Abstract
IDH1 mutations are common in low-grade gliomas and secondary glioblastomas and cause overproduction of (R)-2HG. (R)-2HG modulates the activity of many enzymes, including some that are linked to transformation and some that are probably bystanders. Although prior work on (R)-2HG targets focused on 2OG-dependent dioxygenases, we found that (R)-2HG potently inhibits the 2OG-dependent transaminases BCAT1 and BCAT2, likely as a bystander effect, thereby decreasing glutamate levels and increasing dependence on glutaminase for the biosynthesis of glutamate and one of its products, glutathione. Inhibiting glutaminase specifically sensitized IDH mutant glioma cells to oxidative stress in vitro and to radiation in vitro and in vivo. These findings highlight the complementary roles for BCATs and glutaminase in glutamate biosynthesis, explain the sensitivity of IDH mutant cells to glutaminase inhibitors, and suggest a strategy for maximizing the effectiveness of such inhibitors against IDH mutant gliomas.
Collapse
Affiliation(s)
- Samuel K McBrayer
- Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA 02215, USA
| | - Jared R Mayers
- Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA 02139, USA; Department of Biology, Massachusetts Institute of Technology, Cambridge, MA 02139, USA
| | - Gabriel J DiNatale
- Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA 02215, USA
| | - Diana D Shi
- Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA 02215, USA
| | - Januka Khanal
- Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA 02215, USA
| | - Abhishek A Chakraborty
- Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA 02215, USA
| | - Kristopher A Sarosiek
- John B. Little Center for Radiation Sciences, Department of Environmental Health, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA
| | - Kimberly J Briggs
- Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA 02215, USA
| | - Alissa K Robbins
- Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA 02215, USA
| | - Tomasz Sewastianik
- Department of Oncologic Pathology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Department of Experimental Hematology, Institute of Hematology and Transfusion Medicine, Warsaw, Poland
| | - Sarah J Shareef
- Department of Pathology and Center for Cancer Research, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA; Broad Institute of Harvard and MIT, Cambridge, MA 02142, USA
| | - Benjamin A Olenchock
- Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA 02215, USA; Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA 02139, USA; Department of Biology, Massachusetts Institute of Technology, Cambridge, MA 02139, USA; Division of Cardiovascular Medicine, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA
| | - Seth J Parker
- Department of Bioengineering, University of California, San Diego, La Jolla, CA 92093, USA
| | - Kensuke Tateishi
- Department of Neurosurgery, Translational Neuro-Oncology Laboratory, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02115, USA; Department of Neurosurgery, Yokohama City University, Yokohama, Kanagawa 2360004, Japan
| | - Jessica B Spinelli
- Broad Institute of Harvard and MIT, Cambridge, MA 02142, USA; Department of Cell Biology, Harvard Medical School, Boston, MA 02115, USA
| | - Mirazul Islam
- Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA 02215, USA; Broad Institute of Harvard and MIT, Cambridge, MA 02142, USA
| | - Marcia C Haigis
- Department of Cell Biology, Harvard Medical School, Boston, MA 02115, USA
| | - Ryan E Looper
- Department of Chemistry, University of Utah, Salt Lake City, UT 84112, USA
| | - Keith L Ligon
- Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA 02215, USA; Department of Pathology, Brigham and Women's Hospital, Boston, MA 02115, USA; Department of Pathology, Harvard Medical School, Boston, MA 02115, USA; Department of Pathology, Children's Hospital Boston, Boston, MA 02115, USA
| | - Bradley E Bernstein
- Department of Pathology and Center for Cancer Research, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA; Broad Institute of Harvard and MIT, Cambridge, MA 02142, USA
| | - Ruben D Carrasco
- Department of Oncologic Pathology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Department of Pathology, Brigham and Women's Hospital, Boston, MA 02115, USA
| | - Daniel P Cahill
- Department of Neurosurgery, Translational Neuro-Oncology Laboratory, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02115, USA
| | - John M Asara
- Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA; Cancer Center, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA
| | - Christian M Metallo
- Department of Bioengineering, University of California, San Diego, La Jolla, CA 92093, USA
| | - Neela H Yennawar
- Huck Institutes of the Life Sciences, Pennsylvania State University, University Park, PA 16802, USA
| | - Matthew G Vander Heiden
- Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA 02215, USA; Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA 02139, USA; Department of Biology, Massachusetts Institute of Technology, Cambridge, MA 02139, USA
| | - William G Kaelin
- Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA 02215, USA; Howard Hughes Medical Institute, Chevy Chase, MD 20815, USA.
| |
Collapse
|
17
|
Laukka T, Myllykoski M, Looper RE, Koivunen P. Cancer-associated 2-oxoglutarate analogues modify histone methylation by inhibiting histone lysine demethylases. J Mol Biol 2018; 430:3081-3092. [PMID: 29981745 DOI: 10.1016/j.jmb.2018.06.048] [Citation(s) in RCA: 35] [Impact Index Per Article: 5.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/14/2018] [Revised: 06/26/2018] [Accepted: 06/27/2018] [Indexed: 12/21/2022]
Abstract
Histone lysine demethylases (KDMs) are 2-oxoglutarate-dependent dioxygenases (2-OGDDs) that regulate gene expression by altering chromatin structure. Their dysregulation has been associated with many cancers. We set out to study the catalytic and inhibitory properties of human KDM4A, KDM4B, KDM5B, KDM6A and KDM6B, aiming in particular to reveal which of these enzymes are targeted by cancer-associated 2-oxoglutarate (2-OG) analogues. We used affinity-purified insect cell-produced enzymes and synthetic peptides with trimethylated lysines as substrates for the in vitro enzyme activity assays. In addition, we treated breast cancer cell lines with cell-permeable forms of 2-OG analogues and studied their effects on the global histone methylation state. Our data show that KDMs have substrate specificity. Among the enzymes studied, KDM5B had the highest affinity for the peptide substrate but the lowest affinity for the 2-OG and the Fe2+ cosubstrate/cofactors. R-2-hydroxyglutarate (R-2HG) was the most efficient inhibitor of KDM6A, KDM4A and KDM4B, followed by S-2HG. This finding was supported by accumulations of the histone H3K9me3 and H3K27me3 marks in cells treated with the cell-permeable forms of these compounds. KDM5B was especially resistant to inhibition by R-2HG, while citrate was the most efficient inhibitor of KDM6B. We conclude that KDM catalytic activity is susceptible to inhibition by tumorigenic 2-OG analogues and suggest that the inhibition of KDMs is involved in the disease mechanism of cancers in which these compounds accumulate, such as the isocitrate dehydrogenase mutations.
Collapse
Affiliation(s)
- Tuomas Laukka
- Biocenter Oulu, Faculty of Biochemistry and Molecular Medicine, Oulu Center for Cell-Matrix Research, University of Oulu, FIN-90014 Oulu, Finland
| | - Matti Myllykoski
- Biocenter Oulu, Faculty of Biochemistry and Molecular Medicine, Oulu Center for Cell-Matrix Research, University of Oulu, FIN-90014 Oulu, Finland
| | - Ryan E Looper
- Department of Chemistry, University of Utah, Salt Lake City, UT 84112, USA
| | - Peppi Koivunen
- Biocenter Oulu, Faculty of Biochemistry and Molecular Medicine, Oulu Center for Cell-Matrix Research, University of Oulu, FIN-90014 Oulu, Finland.
| |
Collapse
|
18
|
Bharat D, Cavalcanti RRM, Petersen C, Begaye N, Cutler BR, Costa MMA, Ramos RKLG, Ferreira MR, Li Y, Bharath LP, Toolson E, Sebahar P, Looper RE, Jalili T, Rajasekaran NS, Jia Z, Symons JD, Anandh Babu PV. Blueberry Metabolites Attenuate Lipotoxicity-Induced Endothelial Dysfunction. Mol Nutr Food Res 2017; 62. [PMID: 29024402 DOI: 10.1002/mnfr.201700601] [Citation(s) in RCA: 41] [Impact Index Per Article: 5.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/12/2017] [Revised: 09/18/2017] [Indexed: 01/13/2023]
Abstract
SCOPE Lipotoxicity-induced endothelial dysfunction is an important vascular complication associated with diabetes. Clinical studies support the vascular benefits of blueberry anthocyanins, but the underlying mechanism is unclear. The hypothesis that metabolites of blueberry anthocyanins attenuate lipotoxicity-induced endothelial dysfunction was tested. METHODS AND RESULTS Human aortic endothelial cells (HAECs) were treated for 6 h with either: (i) the parent anthocyanins (malvidin-3-glucoside and cyanidin-3-glucoside); or (ii) the blueberry metabolites (hydroxyhippuric acid, hippuric acid, benzoic acid-4-sulfate, isovanillic acid-3-sulfate, and vanillic acid-4-sulfate), at concentrations known to circulate in humans following blueberry consumption. For the last 5 h HAECs were treated with palmitate or vehicle. HAECs treated with palmitate displayed elevated reactive oxygen species generation, increased mRNA expression of NOX4, chemokines, adhesion molecules, and IκBα, exaggerated monocyte binding, and suppressed nitric oxide production. Of note, the damaging effects of palmitate were ameliorated in HAECs treated with blueberry metabolites but not parent anthocyanins. Further, important translational relevance of these results was provided by our observation that palmitate-induced endothelial dysfunction was lessened in arterial segments that incubated concurrently with blueberry metabolites. CONCLUSION The presented findings indicate that the vascular benefits of blueberry anthocyanins are mediated by their metabolites. Blueberries might complement existing therapies to lessen vascular complications.
Collapse
Affiliation(s)
- Divya Bharat
- Department of Nutrition and Integrative Physiology, College of Health, University of Utah, Salt Lake City, USA
| | | | - Chrissa Petersen
- Department of Nutrition and Integrative Physiology, College of Health, University of Utah, Salt Lake City, USA
| | - Nathan Begaye
- Department of Nutrition and Integrative Physiology, College of Health, University of Utah, Salt Lake City, USA
| | - Brett Ronald Cutler
- Department of Nutrition and Integrative Physiology, College of Health, University of Utah, Salt Lake City, USA
| | - Marcella Melo Assis Costa
- Department of Nutrition and Integrative Physiology, College of Health, University of Utah, Salt Lake City, USA
| | | | - Marina Ramos Ferreira
- Department of Nutrition and Integrative Physiology, College of Health, University of Utah, Salt Lake City, USA
| | - Youyou Li
- Department of Nutrition and Integrative Physiology, College of Health, University of Utah, Salt Lake City, USA
| | - Leena P Bharath
- Department of Nutrition and Integrative Physiology, College of Health, University of Utah, Salt Lake City, USA
| | - Emma Toolson
- Department of Nutrition and Integrative Physiology, College of Health, University of Utah, Salt Lake City, USA
| | - Paul Sebahar
- Synthetic and Medicinal Chemistry Core, University of Utah, Salt Lake City, USA
| | - Ryan E Looper
- Synthetic and Medicinal Chemistry Core, University of Utah, Salt Lake City, USA
| | - Thunder Jalili
- Department of Nutrition and Integrative Physiology, College of Health, University of Utah, Salt Lake City, USA
| | - Namakkal S Rajasekaran
- Cardiac Aging and Redox Signaling Laboratory, Division of Molecular and Cellular Pathology, Department of Pathology, University of Alabama at Birmingham, Birmingham, USA
| | - Zhenquan Jia
- Department of Biology, University of North Carolina at Greensboro, Greensboro, USA
| | - J David Symons
- Department of Nutrition and Integrative Physiology, College of Health, University of Utah, Salt Lake City, USA.,Division of Endocrinology, Metabolism, Diabetes, and Molecular Medicine Program, University of Utah, Salt Lake City, USA
| | - Pon Velayutham Anandh Babu
- Department of Nutrition and Integrative Physiology, College of Health, University of Utah, Salt Lake City, USA
| |
Collapse
|
19
|
Kwon KH, Edwards AV, Yang M, Looper RE. Exploring hydroamination-cycloaddition-fragmentation sequences to access polycyclicguanidines and vinyl-2-aminoimidazoles. Tetrahedron 2017; 73:6067-6079. [PMID: 29681663 DOI: 10.1016/j.tet.2017.08.052] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
Abstract
The intramolecular hydroamination of a guanidine on an eneyne unit affords a guanidine-substituted diene capable of reacting with dienophiles. These substrates undergo [4+2]-cycloaddition reactions to generate a series of complex cyclic- and spirocyclic-guanidines. Select substrates can further undergo a ring opening-elimination cascade that ultimately reveals a vinyl-2-aminoimidazole. As such this cascade reaction may find application in the synthesis of oroidin-type natural products and their analogues.
Collapse
Affiliation(s)
- Ki-Hyeok Kwon
- Department of Chemistry, University of Utah 315 S 1400 E, Salt Lake City, UT 8103, USA
| | - Anne V Edwards
- Department of Chemistry, University of Utah 315 S 1400 E, Salt Lake City, UT 8103, USA
| | - Miao Yang
- Department of Chemistry, University of Utah 315 S 1400 E, Salt Lake City, UT 8103, USA
| | - Ryan E Looper
- Department of Chemistry, University of Utah 315 S 1400 E, Salt Lake City, UT 8103, USA
| |
Collapse
|
20
|
Abstract
A regioselective base-mediated cyclization of mono-N-acylpropargylguanidines is reported. A related Ag(I)-catalyzed hydroamination strategy was recently employed to yield N3-Cbz-protected ene-guanidines, which found utility in the synthesis of naamidine A. Herein, we report the base-catalyzed hydroamination of mono-N-acylpropargylguanidines, which proceeds with the opposite regiochemistry to deliver isomerized N2-acyl-2-aminoimidazoles with broad substrate scope, circumventing the problematic regiospecific acylation of free 2-aminoimidazoles.
Collapse
Affiliation(s)
- Justin M. Salvant
- Department of Chemistry, University of Utah, 315 South 1400 East, Salt Lake City, Utah 84112, United States
| | - Anne V. Edwards
- Department of Chemistry, University of Utah, 315 South 1400 East, Salt Lake City, Utah 84112, United States
| | - Daniel Z. Kurek
- Department of Chemistry, University of Utah, 315 South 1400 East, Salt Lake City, Utah 84112, United States
| | - Ryan E. Looper
- Department of Chemistry, University of Utah, 315 South 1400 East, Salt Lake City, Utah 84112, United States
| |
Collapse
|
21
|
Abstract
A synthesis of the 1,2-isoxazolidine fragment of the potent voltage gated sodium channel blocker, zetekitoxin AB is described. The synthesis utilizes an intramolecular nitrone -olefin 1,3-dipolar cycloaddition to establish the stereochemistry of the cis-1,2-isoxazolidine. The oxidative cleavage of an all anti-triol with the excision of the central carbon is central to using α-D-glucopyranoside as a traceless stereochemical template. This route furnishes a suitably protected synthon for the synthesis of zetekitoxin AB.
Collapse
Affiliation(s)
- Srinivas R Paladugu
- Department of Chemistry, University of Utah, 315 South 1400 East, Salt Lake City, UT 84112
| | - Ryan E Looper
- Department of Chemistry, University of Utah, 315 South 1400 East, Salt Lake City, UT 84112
| |
Collapse
|
22
|
Abstract
A short and scalable synthesis of naamidine A, a marine alkaloid with a selective ability to inhibit epidermal growth factor receptor (EGFR)-dependent cellular proliferation, has been achieved. A key achievement in this synthesis was the development of a regioselective hydroamination of a monoprotected propargylguanidine to deliver N(3)-protected cyclic ene-guanidines. This permits the extension of this methodology to prepare N(2)-acyl analogues in a fashion that obviates the troublesome acylation of the free 2-aminoimidazoles, which typically yields mixtures of N(2)- and N(2),N(2)-diacylated products.
Collapse
Affiliation(s)
- Joseph B. Gibbons
- Department of Chemistry, University of Utah, 315 South 1400
East, Salt Lake City, Utah 84112, United States
| | - Justin M. Salvant
- Department of Chemistry, University of Utah, 315 South 1400
East, Salt Lake City, Utah 84112, United States
| | - Rachel M. Vaden
- Department of Chemistry, University of Utah, 315 South 1400
East, Salt Lake City, Utah 84112, United States
| | - Ki-Hyeok Kwon
- Department of Chemistry, University of Utah, 315 South 1400
East, Salt Lake City, Utah 84112, United States
| | - Bryan E. Welm
- Immunobiology and Cancer Program, Oklahoma Medical Research
Foundation, 825 Northeast 13th Street, Oklahoma City, Oklahoma 73104, United
States
| | - Ryan E. Looper
- Department of Chemistry, University of Utah, 315 South 1400
East, Salt Lake City, Utah 84112, United States
| |
Collapse
|
23
|
Fan J, Teng X, Liu L, Mattaini KR, Looper RE, Vander Heiden MG, Rabinowitz JD. Human phosphoglycerate dehydrogenase produces the oncometabolite D-2-hydroxyglutarate. ACS Chem Biol 2015; 10:510-6. [PMID: 25406093 PMCID: PMC4340346 DOI: 10.1021/cb500683c] [Citation(s) in RCA: 140] [Impact Index Per Article: 15.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/13/2022]
Abstract
![]()
Human d-3-phosphoglycerate dehydrogenase (PHGDH), the
first enzyme in the serine biosynthetic pathway, is genomically amplified
in tumors including breast cancer and melanoma. In PHGDH-amplified cancer cells, knockdown of PHGDH is not fully rescued
by exogenous serine, suggesting possible additional growth-promoting
roles for the enzyme. Here we show that, in addition to catalyzing
oxidation of 3-phosphoglycerate, PHGDH catalyzes NADH-dependent reduction
of α-ketoglutarate (AKG) to the oncometabolite d-2-hydroxyglutarate
(d-2HG). Knockdown of PHGDH decreased cellular 2HG by approximately
50% in the PHGDH-amplified breast cancer cell lines
MDA-MB-468 (normal concentration 93 μM) and BT-20 (normal concentration
35 μM) and overexpression of PHGDH increased cellular 2HG by
over 2-fold in non-PHGDH-amplified MDA-MB-231 breast
cancer cells, which normally display very low PHGDH expression. The
reduced 2HG level in PHGDH knockdown cell lines can be rescued by
PHGDH re-expression, but not by a catalytically inactive PHGDH mutant.
The initial connection between cancer and d-2HG involved
production of high levels of d-2HG by mutant isocitrate dehydrogenase.
More recently, however, elevated d-2HG has been observed
in breast cancer tumors without isocitrate dehydrogenase mutation.
Our results suggest that PHGDH is one source of this d-2HG.
Collapse
Affiliation(s)
- Jing Fan
- Lewis-Sigler
Institute for Integrative Genomics, Princeton University, Princeton, New Jersey 08544, United States
- Department
of Chemistry and Molecular Biology, Princeton University, Princeton, New Jersey 08544, United States
| | - Xin Teng
- Lewis-Sigler
Institute for Integrative Genomics, Princeton University, Princeton, New Jersey 08544, United States
- Department
of Chemistry and Molecular Biology, Princeton University, Princeton, New Jersey 08544, United States
| | - Ling Liu
- Lewis-Sigler
Institute for Integrative Genomics, Princeton University, Princeton, New Jersey 08544, United States
- Department
of Chemistry and Molecular Biology, Princeton University, Princeton, New Jersey 08544, United States
| | - Katherine R. Mattaini
- Koch
Institute and Department of Biology, MIT, Cambridge, Massachusetts 02139, United States
| | - Ryan E. Looper
- Department
of Chemistry, University of Utah, Salt Lake City, Utah 84112, United States
| | - Matthew G. Vander Heiden
- Koch
Institute and Department of Biology, MIT, Cambridge, Massachusetts 02139, United States
- Dana-Farber Cancer Institute, Boston, Massachusetts 02115, United States
| | - Joshua D. Rabinowitz
- Lewis-Sigler
Institute for Integrative Genomics, Princeton University, Princeton, New Jersey 08544, United States
- Department
of Chemistry and Molecular Biology, Princeton University, Princeton, New Jersey 08544, United States
- The Cancer Institute of New Jersey, New Brunswick, New Jersey 08903, United States
| |
Collapse
|
24
|
Affiliation(s)
| | | | - Ryan E. Looper
- Department of Chemistry, University of Utah, Salt Lake City, UT, 84112.
| |
Collapse
|
25
|
Gligorich KM, Vaden RM, Shelton DN, Wang G, Matsen CB, Looper RE, Sigman MS, Welm BE. Development of a screen to identify selective small molecules active against patient-derived metastatic and chemoresistant breast cancer cells. Breast Cancer Res 2014; 15:R58. [PMID: 23879992 PMCID: PMC4028696 DOI: 10.1186/bcr3452] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/28/2012] [Revised: 04/19/2013] [Accepted: 07/23/2013] [Indexed: 12/13/2022] Open
Abstract
Introduction High failure rates of new investigational drugs have impaired the development of breast cancer therapies. One challenge is that excellent activity in preclinical models, such as established cancer cell lines, does not always translate into improved clinical outcomes for patients. New preclinical models, which better replicate clinically-relevant attributes of cancer, such as chemoresistance, metastasis and cellular heterogeneity, may identify novel anti-cancer mechanisms and increase the success of drug development. Methods Metastatic breast cancer cells were obtained from pleural effusions of consented patients whose disease had progressed. Normal primary human breast cells were collected from a reduction mammoplasty and immortalized with human telomerase. The patient-derived cells were characterized to determine their cellular heterogeneity and proliferation rate by flow cytometry, while dose response curves were performed for chemotherapies to assess resistance. A screen was developed to measure the differential activity of small molecules on the growth and survival of patient-derived normal breast and metastatic, chemoresistant tumor cells to identify selective anti-cancer compounds. Several hits were identified and validated in dose response assays. One compound, C-6, was further characterized for its effect on cell cycle and cell death in cancer cells. Results Patient-derived cells were found to be more heterogeneous, with reduced proliferation rates and enhanced resistance to chemotherapy compared to established cell lines. A screen was subsequently developed that utilized both tumor and normal patient-derived cells. Several compounds were identified, which selectively targeted tumor cells, but not normal cells. Compound C-6 was found to inhibit proliferation and induce cell death in tumor cells via a caspase-independent mechanism. Conclusions Short-term culture of patient-derived cells retained more clinically relevant features of breast cancer compared to established cell lines. The low proliferation rate and chemoresistance make patient-derived cells an excellent tool in preclinical drug development.
Collapse
|
26
|
Kwon KH, Serrano CM, Koch M, Barrows LR, Looper RE. Synthesis of bicyclic guanidines via cascade hydroamination/Michael additions of mono-N-acryloylpropargylguanidines. Org Lett 2014; 16:6048-51. [PMID: 25393831 PMCID: PMC4260634 DOI: 10.1021/ol502691w] [Citation(s) in RCA: 24] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Abstract
A cascade silver(I)-catalyzed hydroamination/Michael addition sequence has been developed to deliver highly substituted bicyclic guanidines. This transformation gives rise to geometrically and constitutionally stable ene-guanidines and generates a remote stereocenter with moderate to high diastereoselectivity.
Collapse
Affiliation(s)
- Ki-Hyeok Kwon
- †Department of Chemistry, University of Utah, 315 South 1400 East, Salt Lake City, Utah 84112, United States
| | - Catherine M Serrano
- †Department of Chemistry, University of Utah, 315 South 1400 East, Salt Lake City, Utah 84112, United States
| | - Michael Koch
- ‡Department of Pharmacy/Toxicology, University of Utah, 30 South 2000 East, Salt Lake City, Utah 84112 United States
| | - Louis R Barrows
- ‡Department of Pharmacy/Toxicology, University of Utah, 30 South 2000 East, Salt Lake City, Utah 84112 United States
| | - Ryan E Looper
- †Department of Chemistry, University of Utah, 315 South 1400 East, Salt Lake City, Utah 84112, United States
| |
Collapse
|
27
|
Basham KJ, Leonard CJ, Kieffer C, Shelton DN, McDowell ME, Bhonde VR, Looper RE, Welm BE. Dioxin exposure blocks lactation through a direct effect on mammary epithelial cells mediated by the aryl hydrocarbon receptor repressor. Toxicol Sci 2014; 143:36-45. [PMID: 25265996 DOI: 10.1093/toxsci/kfu203] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
Abstract
In mammals, lactation is a rich source of nutrients and antibodies for newborn animals. However, millions of mothers each year experience an inability to breastfeed. Exposure to several environmental toxicants, including 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD), has been strongly implicated in impaired mammary differentiation and lactation. TCDD and related polyhalogenated aromatic hydrocarbons are widespread industrial pollutants that activate the aryl hydrocarbon receptor (AHR). Despite many epidemiological and animal studies, the molecular mechanism through which AHR signaling blocks lactation remains unclear. We employed in vitro models of mammary differentiation to recapitulate lactogenesis in the presence of toxicants. We demonstrate AHR agonists directly block milk production in isolated mammary epithelial cells. Moreover, we define a novel role for the aryl hydrocarbon receptor repressor (AHRR) in mediating this response. Our mechanistic studies suggest AHRR is sufficient to block transcription of the milk gene β-casein. As TCDD is a prevalent environmental pollutant that affects women worldwide, our results have important public health implications for newborn nutrition.
Collapse
Affiliation(s)
- Kaitlin J Basham
- *Department of Oncological Sciences, Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah 84112, Department of Chemistry, University of Utah, Salt Lake City, Utah 84112 and Department of Surgery, University of Utah, Salt Lake City, Utah 84112
| | - Christopher J Leonard
- *Department of Oncological Sciences, Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah 84112, Department of Chemistry, University of Utah, Salt Lake City, Utah 84112 and Department of Surgery, University of Utah, Salt Lake City, Utah 84112
| | - Collin Kieffer
- *Department of Oncological Sciences, Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah 84112, Department of Chemistry, University of Utah, Salt Lake City, Utah 84112 and Department of Surgery, University of Utah, Salt Lake City, Utah 84112
| | - Dawne N Shelton
- *Department of Oncological Sciences, Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah 84112, Department of Chemistry, University of Utah, Salt Lake City, Utah 84112 and Department of Surgery, University of Utah, Salt Lake City, Utah 84112
| | - Maria E McDowell
- *Department of Oncological Sciences, Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah 84112, Department of Chemistry, University of Utah, Salt Lake City, Utah 84112 and Department of Surgery, University of Utah, Salt Lake City, Utah 84112
| | - Vasudev R Bhonde
- *Department of Oncological Sciences, Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah 84112, Department of Chemistry, University of Utah, Salt Lake City, Utah 84112 and Department of Surgery, University of Utah, Salt Lake City, Utah 84112
| | - Ryan E Looper
- *Department of Oncological Sciences, Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah 84112, Department of Chemistry, University of Utah, Salt Lake City, Utah 84112 and Department of Surgery, University of Utah, Salt Lake City, Utah 84112
| | - Bryan E Welm
- *Department of Oncological Sciences, Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah 84112, Department of Chemistry, University of Utah, Salt Lake City, Utah 84112 and Department of Surgery, University of Utah, Salt Lake City, Utah 84112 *Department of Oncological Sciences, Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah 84112, Department of Chemistry, University of Utah, Salt Lake City, Utah 84112 and Department of Surgery, University of Utah, Salt Lake City, Utah 84112
| |
Collapse
|
28
|
Basham KJ, Bhonde VR, Kieffer C, Mack JBC, Hess M, Welm BE, Looper RE. Bis-aryloxadiazoles as effective activators of the aryl hydrocarbon receptor. Bioorg Med Chem Lett 2014; 24:2473-6. [PMID: 24767852 DOI: 10.1016/j.bmcl.2014.04.013] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/31/2014] [Revised: 04/02/2014] [Accepted: 04/04/2014] [Indexed: 12/19/2022]
Abstract
Bis-aryloxadiazoles are common scaffolds in medicinal chemistry due to their wide range of biological activities. Previously, we identified a 1,2,4-bis-aryloxadiazole that blocks mammary branching morphogenesis through activation of the aryl hydrocarbon receptor (AHR). In addition to defects in mammary differentiation, AHR stimulation induces toxicity in many other tissues. We performed a structure activity relationship (SAR) study of 1,2,4-bis-aryloxadiazole to determine which moieties of the molecule are critical for AHR activation. We validated our results with a functional biological assay, using desmosome formation during mammary morphogenesis to indicate AHR activity. These findings will aid the design of oxadiazole derivative therapeutics with reduced off-target toxicity profiles.
Collapse
Affiliation(s)
- Kaitlin J Basham
- Department of Oncological Sciences, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT 84112, USA
| | - Vasudev R Bhonde
- Department of Chemistry, University of Utah, Salt Lake City, UT 84112, USA
| | - Collin Kieffer
- Department of Oncological Sciences, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT 84112, USA
| | - James B C Mack
- Department of Chemistry, University of Utah, Salt Lake City, UT 84112, USA
| | - Matthew Hess
- Department of Chemistry, University of Utah, Salt Lake City, UT 84112, USA
| | - Bryan E Welm
- Department of Oncological Sciences, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT 84112, USA; Department of Surgery, University of Utah, Salt Lake City, UT 84112, USA
| | - Ryan E Looper
- Department of Chemistry, University of Utah, Salt Lake City, UT 84112, USA.
| |
Collapse
|
29
|
Abstract
Cationic Rh(II) complexes are able to catalyze the regioselective hydroamination of propargyl ureas in a 6-endo fashion. This transformation permits access to interesting substitution patterns of dihydropyrimidines which have found use as nucleotide exchange factor inhibitors.
Collapse
Affiliation(s)
- Miao Yang
- Department of Chemistry, University of Utah, Salt Lake City, UT 84112, United States
| | - Shannon J. Odelberg
- Department of Medicine, Cardiology Division, University of Utah, Salt Lake City, UT 84132, United States
- Program in Molecular Medicine, University of Utah, Salt Lake City, UT 84112, United States
- Navigen Inc., Salt Lake City, UT 84108, United States
| | | | - Dean Y. Li
- Department of Medicine, Cardiology Division, University of Utah, Salt Lake City, UT 84132, United States
- Program in Molecular Medicine, University of Utah, Salt Lake City, UT 84112, United States
- Department of Oncology, University of Utah, Salt Lake City, UT 84112, United States
| | - Ryan E. Looper
- Department of Chemistry, University of Utah, Salt Lake City, UT 84112, United States
| |
Collapse
|
30
|
Vaden RM, Gligorich KM, Shelton DN, Wang G, Matsen CB, Looper RE, Sigman MS, Welm BE. Abstract B05: Targeting nonapoptotic cell death in chemoresistant patient-derived breast cancer cells. Mol Cancer Ther 2013. [DOI: 10.1158/1535-7163.pms-b05] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
The development of anti-cancer therapeutics that target non-apoptotic pathways has received increasing attention from the scientific community in recent years. The prevalence of chemoresistance and the characterization of defective apoptotic pathways in cancer has promoted interest in the expansion of current therapeutic regimens to include drugs that induce non-apoptotic cell death. From a phenotypic screen we have identified a small molecule named C6 that induces caspase-independent, non-apoptotic cell death in chemoresistant patient-derived breast cancer cells. Additionally, C6 is also selectively cytotoxic against cancer cells compared to normal mammary epithelial cells. In an effort to characterize this small molecule's mechanism of action and identify relevant biological pathways that might be used as therapeutic drug targets, we have utilized a photoaffinity pull-down strategy to identify biological binding partners of C6. Our photoaffinity pull-down studies have revealed Mitsugumin 23 (MG23), an endoplasmic reticulum-bound transmembrane protein capable of ion channel formation, as a binding partner for C6. Additionally, we have identified a metabolic component of C6-induced cell death through the use of mitochondrial respiration measurements, metabolomic analyses, and mitochondrial transmission electron microscopy (TEM) imaging. Metabolic studies have identified mitochondrial respiration defects, excess lactic acid production, and gross changes in mitochondrial morphology as a result of C6 treatment. Collectively, our findings suggest a role for ionic imbalance and subsequent metabolic disruption in this form of caspase-independent cell death. Our ongoing work is focused on further mechanistic characterization of this non-apoptotic pathway as a potential target for breast cancer drug development.
Citation Format: Rachel M. Vaden, Keith M. Gligorich, Dawne N. Shelton, Guoying Wang, Cindy B. Matsen, Ryan E. Looper, Matthew S. Sigman, Bryan E. Welm. Targeting nonapoptotic cell death in chemoresistant patient-derived breast cancer cells. [abstract]. In: Proceedings of the AACR Precision Medicine Series: Synthetic Lethal Approaches to Cancer Vulnerabilities; May 17-20, 2013; Bellevue, WA. Philadelphia (PA): AACR; Mol Cancer Ther 2013;12(5 Suppl):Abstract nr B05.
Collapse
Affiliation(s)
- Rachel M. Vaden
- Huntsman Cancer Institute, University of Utah, Salt Lake City, UT
| | | | - Dawne N. Shelton
- Huntsman Cancer Institute, University of Utah, Salt Lake City, UT
| | - Guoying Wang
- Huntsman Cancer Institute, University of Utah, Salt Lake City, UT
| | - Cindy B. Matsen
- Huntsman Cancer Institute, University of Utah, Salt Lake City, UT
| | - Ryan E. Looper
- Huntsman Cancer Institute, University of Utah, Salt Lake City, UT
| | | | - Bryan E. Welm
- Huntsman Cancer Institute, University of Utah, Salt Lake City, UT
| |
Collapse
|
31
|
Losman JA, Looper RE, Koivunen P, Lee S, Schneider RK, McMahon C, Cowley GS, Root DE, Ebert BL, Kaelin WG. (R)-2-hydroxyglutarate is sufficient to promote leukemogenesis and its effects are reversible. Science 2013; 339:1621-5. [PMID: 23393090 DOI: 10.1126/science.1231677] [Citation(s) in RCA: 566] [Impact Index Per Article: 51.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/17/2023]
Abstract
Mutations in IDH1 and IDH2, the genes coding for isocitrate dehydrogenases 1 and 2, are common in several human cancers, including leukemias, and result in overproduction of the (R)-enantiomer of 2-hydroxyglutarate [(R)-2HG]. Elucidation of the role of IDH mutations and (R)-2HG in leukemogenesis has been hampered by a lack of appropriate cell-based models. Here, we show that a canonical IDH1 mutant, IDH1 R132H, promotes cytokine independence and blocks differentiation in hematopoietic cells. These effects can be recapitulated by (R)-2HG, but not (S)-2HG, despite the fact that (S)-2HG more potently inhibits enzymes, such as the 5'-methylcytosine hydroxylase TET2, that have previously been linked to the pathogenesis of IDH mutant tumors. We provide evidence that this paradox relates to the ability of (S)-2HG, but not (R)-2HG, to inhibit the EglN prolyl hydroxylases. Additionally, we show that transformation by (R)-2HG is reversible.
Collapse
Affiliation(s)
- Julie-Aurore Losman
- Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA
| | | | | | | | | | | | | | | | | | | |
Collapse
|
32
|
Basham KJ, Kieffer C, Shelton DN, Leonard CJ, Bhonde VR, Vankayalapati H, Milash B, Bearss DJ, Looper RE, Welm BE. Chemical genetic screen reveals a role for desmosomal adhesion in mammary branching morphogenesis. J Biol Chem 2012; 288:2261-70. [PMID: 23212921 PMCID: PMC3554898 DOI: 10.1074/jbc.m112.411033] [Citation(s) in RCA: 18] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/10/2023] Open
Abstract
During the process of branching morphogenesis, the mammary gland undergoes distinct phases of remodeling to form an elaborate ductal network that ultimately produces and delivers milk to newborn animals. These developmental events rely on tight regulation of critical cellular pathways, many of which are probably disrupted during initiation and progression of breast cancer. Transgenic mouse and in vitro organoid models previously identified growth factor signaling as a key regulator of mammary branching, but the functional downstream targets of these pathways remain unclear. Here, we used purified primary mammary epithelial cells stimulated with fibroblast growth factor-2 (FGF2) to model mammary branching morphogenesis in vitro. We employed a forward chemical genetic approach to identify modulators of this process and describe a potent compound, 1023, that blocks FGF2-induced branching. In primary mammary epithelial cells, we used lentivirus-mediated knockdown of the aryl hydrocarbon receptor (AHR) to demonstrate that 1023 acts through AHR to block branching. Using 1023 as a tool, we identified desmosomal adhesion as a novel target of AHR signaling and show that desmosomes are critical for AHR agonists to block branching. Our findings support a functional role for desmosomes during mammary morphogenesis and also in blocking FGF-induced invasion.
Collapse
Affiliation(s)
- Kaitlin J Basham
- Department of Oncological Sciences, Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah 84112, USA
| | | | | | | | | | | | | | | | | | | |
Collapse
|
33
|
Abstract
Syntheses of the reported structures of kealiinines B and C have been executed. An intermolecular electrophile-induced cyclization of a pendant arene on an ene-guanidine affords the tetracyclic, oxidized naphthimidazole cores.
Collapse
Affiliation(s)
- Joseph B. Gibbons
- Department of Chemistry, University of Utah, 315 South 1400 East, Salt Lake City, UT 84112-0850
| | - Keith M. Gligorich
- Department of Surgery, Huntsman Cancer Institute, 2000 Circle of Hope, Salt Lake City, Utah 84112
| | - Bryan E. Welm
- Department of Surgery, Huntsman Cancer Institute, 2000 Circle of Hope, Salt Lake City, Utah 84112
| | - Ryan E. Looper
- Department of Chemistry, University of Utah, 315 South 1400 East, Salt Lake City, UT 84112-0850
| |
Collapse
|
34
|
Abstract
A synthetic strategy to establish five contiguous stereocenters, in a stereocontrolled manner, on the core structure of pactamycin is described. This sequence exploits the use of a Lewis acid mediated epoxide opening cascade to set the relative configuration of the C4-C5 diol while reversing the configuration at C7. This sequence provides the oxygenated core of pactamycin in just 11 steps.
Collapse
Affiliation(s)
- Travis J Haussener
- Department of Chemistry, University of Utah , Salt Lake City, Utah 84112, United States
| | | |
Collapse
|
35
|
Abstract
A concise stereoselective total synthesis of (+)-saxitoxin is described. A silver(I)-initiated hydroamination cascade constructs the bicyclic guanidinium ion core from a alkynyl bisguanidine. This sequence creates two C-N bonds, one C-O bond, and three rings and forms a single stereoisomer in a single synthetic transformation. This process enabled us to complete the synthesis of (+)-saxitoxin in 14 steps from N-Boc-l-serine methyl ester.
Collapse
Affiliation(s)
- Vasudev R Bhonde
- Department of Chemistry, University of Utah, Salt Lake City, Utah 84112, USA
| | | |
Collapse
|
36
|
Affiliation(s)
- Catherine M. Serrano
- Department of Chemistry, University of Utah, 315 South 1400 East, Salt Lake City, Utah 84112, United States
| | - Ryan E. Looper
- Department of Chemistry, University of Utah, 315 South 1400 East, Salt Lake City, Utah 84112, United States
| |
Collapse
|
37
|
Abstract
A simple and efficient one-pot method for the synthesis of monoprotected guanidines is presented. Treatment of an acylcyanamide with chlorotrimethylsilane generates a reactive N-silylcarbodiimide capable of guanylating a variety of amines. Typically the reaction is complete in 15 min for primary and secondary aliphatic amines at rt. Hindered amines and anilines are also competent nucleophiles but require extended reaction times.
Collapse
Affiliation(s)
- Ryan E Looper
- Department of Chemistry, University of Utah, 315 South 1400 East, Salt Lake City, Utah 84112, USA.
| | | | | |
Collapse
|
38
|
Gainer MJ, Bennett NR, Takahashi Y, Looper RE. Regioselective rhodium(II)-catalyzed hydroaminations of propargylguanidines. Angew Chem Int Ed Engl 2010; 50:684-7. [PMID: 21226153 DOI: 10.1002/anie.201006087] [Citation(s) in RCA: 91] [Impact Index Per Article: 6.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/28/2010] [Indexed: 11/11/2022]
Affiliation(s)
- Morgan J Gainer
- Department of Chemistry, University of Utah, 315 South 1400 East, Salt Lake City, UT 84112, USA
| | | | | | | |
Collapse
|
39
|
Gainer MJ, Bennett NR, Takahashi Y, Looper RE. Regioselective Rhodium(II)-Catalyzed Hydroaminations of Propargylguanidines. Angew Chem Int Ed Engl 2010. [DOI: 10.1002/ange.201006087] [Citation(s) in RCA: 28] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
|
40
|
Giles RL, Nkansah RA, Looper RE. Synthesis of 2-Thio- and 2-Oxoimidazoles via Cascade Addition−Cycloisomerization Reactions of Propargylcyanamides. J Org Chem 2009; 75:261-4. [DOI: 10.1021/jo902326d] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Affiliation(s)
- Robert L. Giles
- Department of Chemistry, University of Utah, 315 South 1400 East, Salt lake City, Utah 84112
| | - Richard A. Nkansah
- Department of Chemistry, University of Utah, 315 South 1400 East, Salt lake City, Utah 84112
| | - Ryan E. Looper
- Department of Chemistry, University of Utah, 315 South 1400 East, Salt lake City, Utah 84112
| |
Collapse
|
41
|
Looper RE, Pizzirani D, Schreiber SL. Macrocycloadditions Leading to Conformationally Restricted Small Molecules. Org Lett 2009. [DOI: 10.1021/ol901316r] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
42
|
Abstract
[reaction: see text] The Cu(I)-catalyzed cycloaddition of alkynes and azides (click reaction) provides a robust method for the construction of macrocyclic small molecules via an intramolecular macrocycloaddition. A three-subunit system has been used to explore the tolerance of this macrocycloaddition to variations of stereochemistries and substituents.
Collapse
Affiliation(s)
- Ryan E Looper
- Howard Hughes Medical Institute, Department of Chemistry and Chemical Biology, Harvard University, Broad Institute of Harvard and MIT, Cambridge, Massachusetts 02138, USA
| | | | | |
Collapse
|
43
|
Looper RE, Runnegar MTC, Williams RM. Synthesis of the Putative Structure of 7-Deoxycylindrospermopsin: C7 Oxygenation Is Not Required for the Inhibition of Protein Synthesis. Angew Chem Int Ed Engl 2005. [DOI: 10.1002/ange.200500520] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022]
|
44
|
Looper RE, Runnegar MTC, Williams RM. Synthesis of the Putative Structure of 7-Deoxycylindrospermopsin: C7 Oxygenation Is Not Required for the Inhibition of Protein Synthesis. Angew Chem Int Ed Engl 2005; 44:3879-81. [PMID: 15900531 DOI: 10.1002/anie.200500520] [Citation(s) in RCA: 60] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Affiliation(s)
- Ryan E Looper
- Department of Chemistry, Colorado State University, Fort Collins, CO 80523, USA
| | | | | |
Collapse
|
45
|
Vyvyan JR, Loitz C, Looper RE, Mattingly CS, Peterson EA, Staben ST. Synthesis of aromatic bisabolene natural products via palladium-catalyzed cross-couplings of organozinc reagents. J Org Chem 2004; 69:2461-8. [PMID: 15049646 DOI: 10.1021/jo035778s] [Citation(s) in RCA: 42] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Abstract
Aromatic bisabolene derivatives were prepared by two methods involving cross-coupling of organozinc reagents. The first synthesis of (+/-)-glandulone A (10), as well as syntheses of (+/-)-curcuhydroquinone (8) and (+/-)-curcuquinone (9), were accomplished via coupling of a secondary alkyl zinc reagent (1,5-dimethyl-4-hexenylzinc halide, 18) to protected bromohydroquinones using Pd(dppf)Cl(2) as catalyst. Coupling of arylzinc halides with alkenyl triflate 16 using Pd(PPh(3))(4) catalyst provided a number of bisabolene derivatives and led to syntheses of dehydro-alpha-curcumene (2), (+/-)-curcuphenol (3), and (+/-)-elvirol (13). A high-yield synthesis of the (+/-)-heliannuol D precursor 29 is also reported using this method.
Collapse
Affiliation(s)
- James R Vyvyan
- Department of Chemistry, Western Washington University, Bellingham, Washington 98225-9150, USA.
| | | | | | | | | | | |
Collapse
|
46
|
Affiliation(s)
- Ryan E Looper
- Department of Chemistry, Colorado State University, Fort Collins, CO 80523, USA
| | | |
Collapse
|
47
|
|
48
|
Looper RE, Williams RM. Construction of the A-ring of cylindrospermopsin via an intramolecular oxazinone-N-oxide dipolar cycloaddition. Tetrahedron Lett 2001. [DOI: 10.1016/s0040-4039(00)01921-3] [Citation(s) in RCA: 27] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
49
|
|